Compugen (CGEN) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Rodman & Renshaw Reiterates Buy Rating on Compugen (CGEN)
March 4, 2025 10:26 AM ESTRodman & Renshaw analyst Tony Blair reiterated a Buy rating and $4.00 price target on Compugen (NASDAQ: CGEN).
The analyst comments "This morning, before the market opened, Compugen Ltd. (CGEN; Buy) released its business updates for 4Q24. The company reported an ending cash balance of $103.3 million for the quarter, which is expected to provide funding into 2027. CGEN remains on track to initiate a randomized adaptive platform trial in 2Q25 to... More



